ArticleBMC cancer2026
External validation of predictive models for high-grade cervical lesions in Thai women undergoing colposcopy: a retrospective external validation study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPredictive models for high-grade cervical lesions (CIN2+/HSIL) have been developed in various populations; however, their generalizability across different healthcare settings is uncertain. External validation in specific populations is required before clinical implementation.
methodsThis retrospective external validation study included Thai women who underwent colposcopy between 2022 and 2024 at a tertiary referral center. The primary outcome was histologically confirmed CIN2+/HSIL. Two previously published predictive models were applied without any modifications. Model performance was evaluated in terms of discrimination using the area under the receiver operating characteristic curve (AUROC), calibration using calibration plots, calibration metrics, Brier scores, and clinical utility using decision curve analysis.
resultsA total of 536 women were included, of whom 28.7% were diagnosed with CIN2+/HSIL. Despite differences in demographic characteristics, HPV genotype distribution, cytological findings, and colposcopic features compared to the original development cohorts, both models demonstrated good performance in the Thai population. The Xue model demonstrated good discrimination, with an AUROC of 0.82 (95% CI: 0.77-0.86), whereas the Sheng model demonstrated good discrimination, with an AUROC of 0.80 (95% CI: 0.77-0.85). Both models showed acceptable calibration. The Xue model had a calibration-in-the-large of 0.03 (95% CI: -0.22 to 0.28) and a calibration slope of 0.77 (95% CI: 0.64-0.91), indicating mild overfitting that may benefit from recalibration. The Sheng model showed good calibration, with a slope of 0.88 (95% CI: 0.68-1.08) and a calibration-in-the-large of 0.17 (95% CI: -0.05 to 0.38). Brier scores were 0.148 and 0.163, respectively. Decision curve analysis demonstrated a positive net clinical benefit across clinically relevant threshold probabilities. At the original model-specific predefined probability thresholds, the Xue model achieved a sensitivity of 56.5% and specificity of 93.7%, whereas the Sheng model achieved a sensitivity of 93.5% and specificity of 34.3%, demonstrating a marked trade-off that highlights the importance of threshold selection.
conclusionsBoth predictive models showed good external validity and clinical utility in Thai patients undergoing colposcopy. These findings support individualized risk stratification in women with abnormal screening results to guide clinical decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.